Both in Biotechnology
Outlook Therapeutics vs enGene Therapeutics
Over the past year OTLK returned −62.8% and ENGN returned −78.8%; their daily moves had a correlation of 0.06.
OTLK −62.8% ENGN −78.8%Growth of $1, one year, split-adjusted
| Metric | OTLK | ENGN |
|---|---|---|
| Price | $0.4681 | $1.53 |
| Market cap | $114.0M | $102.5M |
| Today | −5.15% | 0.00% |
| 1 month | −18.6% | −22.7% |
| 6 months | +78.5% | −78.9% |
| Year to date | −70.4% | −83.1% |
| 1 year | −63.4% | −79.1% |
| Revenue growth (YoY) | −99.4% | — |
| Gross margin | −95.0% | — |
| Net margin | −233554.9% | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | -$7.0M | $241.0M |
| Dividend yield | — | — |
| Volatility (60d) | 93.9% | 51.8% |
| Short % of float | 39.3% | 3.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).